Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
Journal of Medicinal Chemistry
|
July 11, 2006
Iron binding dendrimers: a novel approach for the treatment of haemochromatosis
Tao Zhou, Hendrik Neubert, Ding Yong Liu, et al.
The AAPS Journal
|
December 20, 2022
Development and Validation of a Western Blot Method to Quantify Mini-Dystrophin in Human Skeletal Muscle Biopsies
Catherine I Soderstrom, Jennifer Larsen, Carolina Owen, et al.
Frontiers in Bioinformatics
|
October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs
Georgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Gene Therapy
|
November 5, 2021
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Vahid Farrokhi, Jason Walsh, Joe Palandra, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 30, 2019
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Hannah M Jones, Zhiwei Zhang, Paul Jasper, et al.
Clinical Chemistry
|
February 11, 2020
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography-Tandem Mass Spectrometry: Current State and Future Vision
Hendrik Neubert, Christopher M Shuford, Timothy V Olah, et al.
Journal of Neurology
|
January 12, 2017
Reduced serum myostatin concentrations associated with genetic muscle disease progression
Peter M Burch, Oksana Pogoryelova, Joe Palandra, et al.
Therapeutic Advances in Gastroenterology
|
February 13, 2026
Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
Stefan Schreiber, Silvio Danese, Séverine Vermeire, et al.
Frontiers in Immunology
|
September 30, 2022
HLAII peptide presentation of infliximab increases when complexed with TNF
Andrea Casasola-LaMacchia, Robert Joseph Seward, Sophie Tourdot, et al.
Molecular Therapy. Methods & Clinical Development
|
September 25, 2023
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy
Caroline Le Guiner, Xiao Xiao, Thibaut Larcher, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
Journal of Medicinal Chemistry
|
July 11, 2006
Iron binding dendrimers: a novel approach for the treatment of haemochromatosis
Tao Zhou, Hendrik Neubert, Ding Yong Liu, et al.
The AAPS Journal
|
December 20, 2022
Development and Validation of a Western Blot Method to Quantify Mini-Dystrophin in Human Skeletal Muscle Biopsies
Catherine I Soderstrom, Jennifer Larsen, Carolina Owen, et al.
Frontiers in Bioinformatics
|
October 28, 2022
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs
Georgi I Kapitanov, Jeffrey R Chabot, Jatin Narula, et al.
Gene Therapy
|
November 5, 2021
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Vahid Farrokhi, Jason Walsh, Joe Palandra, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 30, 2019
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Hannah M Jones, Zhiwei Zhang, Paul Jasper, et al.
Clinical Chemistry
|
February 11, 2020
Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography-Tandem Mass Spectrometry: Current State and Future Vision
Hendrik Neubert, Christopher M Shuford, Timothy V Olah, et al.
Journal of Neurology
|
January 12, 2017
Reduced serum myostatin concentrations associated with genetic muscle disease progression
Peter M Burch, Oksana Pogoryelova, Joe Palandra, et al.
Therapeutic Advances in Gastroenterology
|
February 13, 2026
Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
Stefan Schreiber, Silvio Danese, Séverine Vermeire, et al.
Frontiers in Immunology
|
September 30, 2022
HLAII peptide presentation of infliximab increases when complexed with TNF
Andrea Casasola-LaMacchia, Robert Joseph Seward, Sophie Tourdot, et al.
Molecular Therapy. Methods & Clinical Development
|
September 25, 2023
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy
Caroline Le Guiner, Xiao Xiao, Thibaut Larcher, et al.
Page
of 8